{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:00:20Z","timestamp":1789164020225,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T00:00:00Z","timestamp":1433808000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12955-015-0279-4","type":"journal-article","created":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T05:35:05Z","timestamp":1433741705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents \u2013 a randomized, prospective, crossover, open clinical trial"],"prefix":"10.1186","volume":"13","author":[{"given":"Norbert","family":"Hermanns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kulzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Landgraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlheinz","family":"Theobald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Haak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,9]]},"reference":[{"issue":"6","key":"279_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","volume":"141","author":"E Selvin","year":"2004","unstructured":"Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421\u201331.","journal-title":"Ann Intern Med"},{"issue":"7258","key":"279_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed). 2000;321(7258):405\u201312.","journal-title":"BMJ (Clinical research ed)"},{"issue":"21","key":"279_CR3","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Jama. 1999;281(21):2005\u201312.","journal-title":"Jama"},{"issue":"2","key":"279_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2337\/diacare.28.2.254","volume":"28","author":"HU Janka","year":"2005","unstructured":"Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254\u20139.","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"279_CR5","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1002\/dmrr.304","volume":"18","author":"H Yki-Jarvinen","year":"2002","unstructured":"Yki-Jarvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2002;18 Suppl 3:S77\u201381.","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"279_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.2337\/diacare.23.5.644","volume":"23","author":"L Heinemann","year":"2000","unstructured":"Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644\u20139.","journal-title":"Diabetes Care"},{"issue":"3","key":"279_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jdiacomp.2007.01.001","volume":"21","author":"W Duckworth","year":"2007","unstructured":"Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complicat. 2007;21(3):196\u2013204.","journal-title":"J Diabetes Complicat"},{"issue":"4","key":"279_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","volume":"37","author":"FG Eliaschewitz","year":"2006","unstructured":"Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of medical research. 2006;37(4):495\u2013501.","journal-title":"Archives of medical research"},{"issue":"4","key":"279_CR9","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2337\/diacare.28.4.950","volume":"28","author":"J Rosenstock","year":"2005","unstructured":"Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28(4):950\u20135.","journal-title":"Diabetes Care"},{"issue":"8","key":"279_CR10","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","volume":"23","author":"H Yki-Jarvinen","year":"2000","unstructured":"Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901\/3002 Study Group. Diabetes Care. 2000;23(8):1130\u20136.","journal-title":"Diabetes Care"},{"issue":"3","key":"279_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","volume":"49","author":"H Yki-Jarvinen","year":"2006","unstructured":"Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442\u201351.","journal-title":"Diabetologia"},{"issue":"3","key":"279_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/0145721708317869","volume":"34","author":"ME Larkin","year":"2008","unstructured":"Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes educ. 2008;34(3):511\u20137.","journal-title":"Diabetes educ"},{"issue":"10 Suppl","key":"279_CR13","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.amjmed.2014.07.003","volume":"127","author":"S Edelman","year":"2014","unstructured":"Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med. 2014;127(10 Suppl):S11\u20136.","journal-title":"Am J Med"},{"issue":"10","key":"279_CR14","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.2337\/diacare.28.10.2543","volume":"28","author":"WH Polonsky","year":"2005","unstructured":"Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543\u20135.","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"279_CR15","first-page":"Abstract 205","volume":"43","author":"E Witthaus","year":"2000","unstructured":"Witthaus E, Stewart J, Bradley C. Improved psychological outcomes after initiation of insulin treatment in patients with type II diabetes. Diabetologia. 2000;43 Suppl 1:Abstract 205.","journal-title":"Diabetologia"},{"issue":"23","key":"279_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1055\/s-0029-1222595","volume":"134","author":"H Hauner","year":"2009","unstructured":"Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T. Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany. Dtsch Med Wochenschr. 2009;134(23):1207\u201313.","journal-title":"Dtsch Med Wochenschr"},{"issue":"Suppl 1","key":"279_CR17","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.2337\/dc08-S012","volume":"31","author":"A American Diabetes","year":"2008","unstructured":"American Diabetes A. Standards of medical care in diabetes\u20132008. Diabetes Care. 2008;31 Suppl 1:S12\u201354.","journal-title":"Diabetes Care"},{"issue":"1","key":"279_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2165\/11319510-000000000-00000","volume":"3","author":"J Moock","year":"2010","unstructured":"Moock J, Hessel F, Ziegeler D, Kubiak T, Kohlmann T. Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ). The patient. 2010;3(1):45\u201358.","journal-title":"The patient"},{"issue":"5","key":"279_CR19","doi-asserted-by":"publisher","first-page":"760","DOI":"10.2337\/diacare.20.5.760","volume":"20","author":"GW Welch","year":"1997","unstructured":"Welch GW, Jacobson AM, Polonsky WH. The Problem Areas in Diabetes Scale. An evaluation of its clinical utility. Diabetes care. 1997;20(5):760\u20136.","journal-title":"Diabetes care"},{"issue":"3","key":"279_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00125-005-0094-2","volume":"49","author":"N Hermanns","year":"2006","unstructured":"Hermanns N, Kulzer B, Krichbaum M, Kubiak T, Haak T. How to screen for depression and emotional problems in patients with diabetes: comparison of screening characteristics of depression questionnaires, measurement of diabetes-specific emotional problems and standard clinical assessment. Diabetologia. 2006;49(3):469\u201377.","journal-title":"Diabetologia"},{"issue":"3","key":"279_CR21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220\u201333.","journal-title":"Med Care"},{"issue":"3","key":"279_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health policy. 1990;16(3):199\u2013208.","journal-title":"Health policy"},{"issue":"2","key":"279_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10198-004-0264-z","volume":"6","author":"W Greiner","year":"2005","unstructured":"Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. The European journal of health economics : HEPAC : health economics in prevention and care. 2005;6(2):124\u201330.","journal-title":"The European journal of health economics : HEPAC : health economics in prevention and care"},{"issue":"3","key":"279_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/s-2003-39080","volume":"35","author":"M Massi Benedetti","year":"2003","unstructured":"Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone and metabolic research\u2009=\u2009Hormon- und Stoffwechselforschung\u2009=\u2009Hormones et metabolisme. 2003;35(3):189\u201396.","journal-title":"Hormone and metabolic research\u2009=\u2009Hormon- und Stoffwechselforschung\u2009=\u2009Hormones et metabolisme"},{"key":"279_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1477-7525-5-57","volume":"5","author":"C Bradley","year":"2007","unstructured":"Bradley C, Plowright R, Stewart J, Valentine J, Witthaus E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes. 2007;5:57.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"279_CR26","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","volume":"26","author":"MC Riddle","year":"2003","unstructured":"Riddle MC, Rosenstock J, Gerich J, Insulin Glargine Study I. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080\u20136.","journal-title":"Diabetes Care"},{"issue":"3","key":"279_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.diabres.2012.01.002","volume":"96","author":"AJ Green","year":"2012","unstructured":"Green AJ, Fox KM, Grandy S. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012;96(3):313\u20138.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"279_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jdiacomp.2012.05.002","volume":"26","author":"SA Williams","year":"2012","unstructured":"Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complicat. 2012;26(5):399\u2013406.","journal-title":"J Diabetes Complicat"},{"issue":"1","key":"279_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1046\/j.1463-1326.1999.00007.x","volume":"1","author":"JC Lopez-Alvarenga","year":"1999","unstructured":"Lopez-Alvarenga JC, Aguilar-Salinas CA, Velasco-Perez ML, Arita-Melzer O, Guillen LE, Wong B, et al. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus. Diabetes Obes Metab. 1999;1(1):29\u201335.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"279_CR30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0026-0495(98)90023-3","volume":"47","author":"A Panahloo","year":"1998","unstructured":"Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metab Clin Exp. 1998;47(6):637\u201343.","journal-title":"Metab Clin Exp"},{"issue":"2","key":"279_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2337\/dc09-1348","volume":"33","author":"M Peyrot","year":"2010","unstructured":"Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240\u20135.","journal-title":"Diabetes Care"},{"issue":"11","key":"279_CR32","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","volume":"28","author":"M Peyrot","year":"2005","unstructured":"Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673\u20139.","journal-title":"Diabetes Care"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-015-0279-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12955-015-0279-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-015-0279-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-015-0279-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:15:30Z","timestamp":1630581330000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-015-0279-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["279"],"URL":"https:\/\/doi.org\/10.1186\/s12955-015-0279-4","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,9]]},"assertion":[{"value":"14 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"77"}}